Sinclair’s team published on partial reprogramming (Yamanaka factors) in mice; translation into safe human therapies is still a long way off.
Human trials show that NMN can raise NAD+ markers; functional anti-ageing outcomes and long-term safety data are still limited.
Early claims about resveratrol as a sirtuin activator have been disputed by several laboratories; oral bioavailability is low.
The ‘What does the science say?’ rating is an estimate by the Engy editors based on the cited source and the wider research. Not medical advice.
Fellow scientists (including Charles Brenner and Matt Kaeberlein) criticise overselling: sirtuin and resveratrol claims that grew bigger in the media than replication allows.
NMN can affect biomarkers, but ‘slows ageing in humans’ is not proven. Sinclair’s mix of academic work, books and company ties makes conflicts of interest relevant to mention.
